Microbot Medical has purchased the US Food and Drug Administration (FDA)-approved devices of Nitiloop for an undisclosed sum.

The acquired assets comprise the NovaCross family of microcatheters, including NovaCross CTO, NovaCross Xtreme and NovaCross BTK.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

These devices enable the intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions (CTO), before percutaneous transluminal coronary angioplasty (PTCA) or stent intervention.

The NovaCross microcatheter family can be used as standalone devices or incorporated into Microbot Medical’s One & Done technology. They are also anticipated to form a collection of customised procedure-related kits for the LIBERTY Robotic System.

Designed to lower capital investment requirements and Cath Lab space, the LIBERTY Robotic System is claimed to be the first-ever disposable endovascular robotic system with remote operation capabilities.

The acquisition of technologies such as the NovaCross Microcatheter family is expected to help Microbot Medical expand its market share in robotics and instruments for endovascular procedures. In the future, the company also aims to use the products to integrate imaging and big data capabilities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Microbot Medical chairman, president and CEO Harel Gadot said: “The addition of Nitiloop’s innovative, FDA-cleared microcatheter family complements the unique robotic ecosystem we are establishing for endovascular procedures.

“This is expected to further assist us in executing our strategic plan of becoming a complete procedure-based company, allowing Microbot Medical to be competitive across the entire endovascular robotic space.

“We believe the NovaCross family of products, once integrated into our existing technology platforms with the LIBERTY Robotic System and our future One & Done technology, will potentially standardise endovascular procedures globally and may finally allow accessibility to robotic technology for the millions that are in dire need of life-saving treatment.”